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INTRODUCTION 
 Ever since man discovered fire, burns are among the oldest 
injuries man still suffers from. Since the days of Eber papyrus in 
ancient Egypt, the treatment of burns has advanced to the present 
day of skin substitutes. Autogenous skin remains the gold standard 
for burn would cover. But the paucity of available donor skin 
provided the impetus to look for materials that would provide 
temporary wound closure. During the recent past the use of 
biological and synthetic material in the temporary closure of the 
wound has become common place. During healing, the 
inflammatory phase is followed by the proliferative phase once the 
fibroblasts arrive and produce collagens, other proteins, 
glycosaminoglycans, the cells of tissue repair, and new capillaries 
in the granulation tissue. 
 Thus, during the granulation tissue formation two major 
extra-cellular matrix proteins – collagen and proteoglycans play an 
important role. 
 Though the efficacy of collagen and the heparin (a 
glycosaminoglycan) have been studied separately and found to be 
effective as against standard care with topical SSD, comparative 
study of burns treated with Heparin as a topical application and 
collagen have not been reported. 
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 In our 50 bedded critical burn centre at the Govt. Kilpauk 
Medical College Hospital, Chennai, where about 7000 outpatients 
of burns are treated with about 1600 in patients annually, the need 
was felt to evaluate the efficacy of topical heparin as against Type I 
collagen  sheets in the management of partial thicken burns as a 
temporary dressing modality.  
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AIM 
 To compare the outcome of partial thickness burns treated 
with topical heparin as against with collagen Type I to evaluate in 
each group the following. 
1. Patient comfort  with parameters like Pain, itching. 
2.  Healing time. 
3. Length of stay in hospital. 
4. The quality of the scar at the end of 6 months. 
5.  The cost benefit analysis. 
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REVIEW OF LITERATURE 
Wound healing is a finely controlled biological process 
involving a series of complex cellular interactions. Following 
inflammation, the wound bed matrix is gradually replaced by 
granulation tissue followed by the long slow process where collagen 
accumulates and restores tensile strength. During healing, the 
inflammatory phase is followed by the proliferative phase once the 
fibroblasts arrive and produce collagen, other proteins, 
glycosaminoglycans, the cells of tissue repair, and new capillaries 
in the granulation tissue. Granulation tissue acts as a precursor to 
the formation of scar tissue. The role played by the extracellular 
matrix proteins from the initial days of healing, particularly during 
granulation tissue formation, is of great importance. Increasing 
evidence is available to show the necessity of appropriate 
extracellular matrix for morphogenesis, cell differentiation and in 
the maintenance of tissue – specific interactions. Along with these 
the cytokines have been implicated during the process of healing. 
During granulation tissue formation two major extracellular matrix 
proteins – collagen and proteoglycans play an important role. 
Collagen is involved from the very early stage to the final 
remodeled tissue formation. The many vital processes of fibroblast 
proliferation, matrix formation and remodeling during tissue repair 
depend on a precise timing and controlled balance in collagen 
synthesis and collagen turnover degradation.  
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                    The Anticoagulant effects of heparin and related 
molecules form the rationale for using heparin in the treatment of 
burns. Recent basic science literature suggests heparin may have a 
biological role as an anti-inflammatory, anti-angiogenic, and anti-
metastatic agent. More importantly, at the molecular level, heparin 
may be an enhancer of wound healing, which has enormous 
implications for the treatment of acute and chronic burn wounds. 
In the immediate post-burn setting, the benefits of heparin’s 
postulated anti-inflammatory and enhanced wound healing 
properties could include reduced pain (hence better compliance 
with dressing changes or physiotherapy), infection, length of 
hospital stay, and mortality. The long-term benefits of this 
expanded range of uses of heparin in the treatment of burn injury 
could include improved function and range of motion of extremities, 
reduced scarring, and possibly decreased psychiatric or 
psychosocial sequalae. 
An expanded range of treatment options for burn injury is 
desirable given that 1.25 million people on average are treated 
annually for burns in the United States. Four percent of these 
people will require hospitalization and specialized burn care. 
Approximately 25 percent of people with severe burn injuries 
(greater than 75 percent of total body surface area) will die even 
after receiving advanced treatment at specialized burn centers. The 
morbidity from burn injury is also great. Short term morbidity 
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includes the pain of the injury and subsequent surgical therapy. 
Over the medium to long term, the psychosocial impact of 
disfigurement, and the potential for post-traumatic stress disorder, 
can have lasting ill effects on patients and patients’ loved ones. The 
following question have to be looked into: 
 Does the method of application make a difference? 
 Do the outcomes vary by the type or degree of burn? 
 How do the outcomes of burn treatment with heparin 
compare to current treatment without heparin? 
Multiple roles for heparin in the treatment of burns were 
examined. These roles included wound healing and pain control, as 
well as the treatment of sepsis, inhalation injury, and venous 
thrombosis. However, there was insufficient data available to 
answer the key question. The research has been conducted in a 
multitude of different countries with varying standards of burn 
care. Thus, the available evidence was severely limited with respect 
to its relevance and applicability to current treatment standards in 
many locales. These deficiencies hampered the ability to judge the 
reported effectiveness of heparin in burn treatment  
These contraindications of the use of Heparin in burns 
include bleeding diathesis, bleeding history, active bleeding or 
associated trauma with potential bleeding, active intestinal ulcer, 
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thrombocytopenia, liver disease, renal disorders, or allergy to 
heparin.  
Saliba et al claimed that heparin had benefits for outcomes 
such as pain, cosmesis, and wound healing. Articles had problems 
regarding the use of invalid comparison groups or invalid outcomes. 
The major issue with comparison groups was the use of controls 
that were treated at earlier points in time, or at different hospitals, 
than people who received heparin. In both cases, different 
treatment protocols could have confounded the observed 
associations between treatment and outcome. 
Regarding outcomes examined using a validated 
measurement instrument such as the McGill Pain Scale or other 
methods like quantity of analgesics required were employed to 
estimate the degree of pain relief in heparin versus control 
patients. For cosmesis, pictures were used to demonstrate the 
benefit associated with heparin use Confounding was not controlled 
in any of the abstracted articles. Furthermore, confounding could 
not be ruled out for the randomized controlled trials The evidence 
from the abstracted articles was not applicable to all clinical 
contexts. This was because the treatment protocols employed in the 
articles did not demonstrate a common standard of burn care. 
Reasons for the absence of commonality were temporal, i.e., the 
research was done before current standards were adopted, or 
contextual, i.e., the research was country specific and standards of 
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burn care differ between countries. If heparin is shown to promote 
wound healing of the donor area, then the next study would involve 
people (adults, adolescents, and children) with bilateral extremity 
burns to the arms, hands, or legs. People would serve as their own 
controls: topical heparin plus standard treatment would be applied 
to one extremity and standard treatment alone would be applied to 
the other extremity. Outcomes would be the same as in the first 
study, plus there would be an evaluation of quality of life. 
All these studies would have to be organized at multiple sites 
to ensure that adequate numbers of patients are recruited to 
achieve high statistical power. 
A general list of potential outcomes includes: 
 Mortality 
 Incidence of medical procedures following initial treatment 
with heparin or standard therapy (e.g., reintubation, 
excision, grafting) 
 Functional performance (e.g., thumb opposition score, 
fingertip-to-palm distance, prehensile score) 
 Pain (measured using the McGill Pain Scale) 
 Scarring (measured using the Vancouver Scar Scale) 
 Itching (measured via the amount of anti-pruritic 
medications used [e.g., Benadryl®]) 
 9
 Quality of Life (measured using the Health Outcomes 
Burn Questionnaire for children and  
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Heparin 
Heparin belongs to a family of polyanionic polysaccharides 
called glycosaminoglycans (GAGs). The structure of GAGs is 
described in terms of their prevalent repeating disaccharide 
sequences, which consist of alternating uronic acid and amino 
sugar residues. Heparin is a highly sulfated polysaccharide 
composed of hexuronic acid and D-glucosamine residues joined by 
glycosidic linkages. Heparin is a polydisperse compound with a 
molecular weight ranging from 3,000 to 30,000 Da (Daltons) (mean 
weight, approximately 15,000 Da). Commercial heparin, or 
unfractionated heparin (UFH), is isolated from mammalian tissues 
rich in mast cells. Heparin acts as an anticoagulant by activating 
antithrombin and accelerating the rate at which antithrombin 
inactivates clotting enzymes, particularly thrombin (factor IIa) and 
factor Xa. UFH also enhances the inhibition of factor IXa, factor 
XIa, and factor VIIa bound to tissue factor by antithrombin. 
Heparin binds to antithrombin through a high affinity 
pentasaccharide, which is present on about one-third of heparin 
molecules. Binding of heparin to antithrombin via its unique 
pentasaccharide sequence causes a conformational change in the 
reactive center loop of antithrombin that accelerates its interaction 
with factor Xa, but not with thrombin. For inhibition of thrombin, 
heparin must bind to both the coagulation enzyme and 
antithrombin. This bridging effect requires a heparin chain that 
contains at least 18 saccharides. By inactivating thrombin, heparin 
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not only prevents fibrin formation, but also inhibits thrombin-
induced activation of platelets and factors V and VIII. 
Besides binding to antithrombin, heparin also binds to a wide 
range of other proteins via electrostatic interactions. These proteins 
include heparin cofactor II, receptors, and growth factors. The 
relative strength of binding depends on the sulfation pattern, 
charge density, and molecular weight 
Low Molecular Weight Heparins 
During the last decade, low molecular weight heparins (LMWHs) 
have gradually replaced UFH for some clinical indications. LMWH 
is prepared from UFH by controlled enzymatic or chemical 
depolymerization. Like heparin, LMWHs are polydisperse and 
comprise heparin chains from 1,000 to 10,000 Da. The mean 
molecular weight of LMWHs is between 3,600 and 6,500 Da. About 
15 to 20 percent of LMWH chains contain the antithrombin-binding 
pentasaccharide sequence. At least half of the pentsaccharide-
containing chains of LMWH are too short to bridge thrombin to 
antithrombin. For this reason, LMWHs have reduced ability to 
inactivate thrombin. In contrast, the smaller molecular weight 
chains retain their ability to inactivate factor Xa because bridging 
between antithrombin and factor Xa is less critical. Compared to 
UFH, LMWHs exhibit a better subcutaneous bioavailability, a more 
predictable anticoagulant response, and a longer half-life.3 More 
 12
recently, synthetic analogs of the antithrombin-binding 
pentasaccharide sequence have been developed. 
Non-Anticoagulant Effects of Heparin 
Heparin possesses both a flexible structure and a high 
anionic charge that permits electrostatic interactions with a variety 
of different molecules. While heparin has been used largely for its 
anticoagulant effects, there is evidence that heparin and related 
molecules also possess anti-inflammatory and antiangiogenic 
properties, as well as a capacity for wound healing. These effects 
are discussed separately below.  
Anti-Inflammatory Effects 
Although the mechanisms responsible for the anticoagulant 
effects of heparin are well understood, the mechanisms underlying 
heparin’s anti-inflammatory activity are not. The evidence that 
heparin possess anti-inflammatory properties comes mainly from 
cell culture and animal studies. The anti-inflammatory and 
immunomodulating effects are far-reaching and include influencing 
monocyte, T-cell and neutrophil activity, nitric oxide production, 
chemokine and cytokine activity, complement activity, platelet 
activation and aggregation, and smooth muscle cell proliferation. 
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Antiangiogenic and Antimetastatic Effects 
There is increasing interest in a potential role for heparin 
and related molecules in the management of cancer patients. 
LMWHs have generated particular interest because they have been 
validated in both the treatment and prevention of thromboembolic 
disease in patients with malignancy. More interestingly, the 
benefits of LMWH therapy appear to be independent of any 
anticoagulant properties, which suggests that direct effects on 
tumor cell biology can help to explain the mechanism. Possible 
mechanisms include the inhibition of selectin-mediated cell-cell 
interactions, heparanase inhibition, binding of proangiogenic 
growth factors (e.g., basic fibroblast growth factor [bFGF] and 
vascular endothelial growth factor [VEGF]), and stimulation of 
tissue factor pathway inhibitor (TFPI) release. 
Wound Healing Effects 
A persistent inflammation with the accumulation of large 
numbers of neutrophils is characteristic of chronic wounds. 
Secretory products released from these cells, such as elastase, 
cathepsin G, and proteinases, are detrimental to wound healing 
because they degrade the extracellular matrix and growth factors 
and further recruit neutrophils to the wound area. Heparin and 
related molecules are thought to inhibit the action of these 
secretary products via electrostatic interactions. 
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Clinical Uses of Heparin 
Since its discovery in 1917, heparin preparations have been 
used as an effective anticoagulant for thromboembolic prophylaxis 
and treatment. With over half a century of use, other roles for 
heparin have been elicited, including angiogenesis regulation, 
lipoprotein lipase modulation, maintenance of endothelial 
competence, and inhibition of vascular smooth muscle proliferation 
after injury. This section will focus on clinically proven and 
accepted applications of heparin. Heparin is the most widely used 
parenteral antithrombotic in clinical medicine due to its ease of 
administration and titration, availability, cost, known side-effect 
profile, and demonstrated clinical efficacy. Other parenteral 
antithrombotic agents available include heparinoids such as 
fondaparinux or direct thrombin inhibitors such as hirudin and 
bivalirudin. These drugs are more expensive, not as easily titrated 
and reversed, and have been studied in fewer clinical applications 
relative to heparin. Numerous guidelines define the role of heparin 
in thrombosis prevention and treatment; the American College of 
Chest Physicians (ACCP) guidelines are perhaps the most 
frequently cited.  
Collagen and Burns 
Collagen is the most common mammalian protein, an 
essential product of fibroblasts. Atleast 17 types of collagen have 
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been identified. The most known skin collagens are Type I, III, IV, 
V, VI  and VII. Type I, III, and V are fibrillar type and are the 
normal components of dermis. 
Fibrillar collagen type I and type III are the primary 
fibroplastic molecules associated with granulation tissue and scars. 
Type III is already forming with in 24 hours of burn injury, 
whereas Type I and its precursor molecule can be seen in  4 to 7 
days. Type III fibrillar collagen is the first to be produced and most 
abundant. This is gradually reversed as the healing progresses and 
Type I becomes more dominant. Mature dermal tissue has a normal 
1:3 collagen ratio of 4:1, however this normal proportion is never 
achieved by scar tissue. 
Burn Injury 
Approximately million people are treated annually for burn 
injuries in India. Four percent of these people require 
hospitalization and specialized burn care. High-risk populations for 
burn injuries include children, elderly, physically or mentally 
disabled.  
Definition and Description of Burn Injury 
Burn injuries are either partial thickness or full thickness in 
nature. Partial thickness burns involve the epidermis and various 
depths of the underlying dermis. These burns are diagnosed both 
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clinically and temporally. Partial thickness burns can be divided 
into superficial or deep Superficial partial thickness burns appear 
as an erythema (first degree) or blistering (second degree) on the 
skin. Very superficial burns correlate with injury to the epithelial 
layer of skin and usually heal without medical intervention or 
scarring (except for possible hyperpigmentation, which is usually 
temporary in nature [e.g., sunburn]). Superficial partial thickness 
burns heal within 7 to 14 days. A superficial partial thickness burn 
may also involve the superficial aspect of the dermis (second 
degree), which can result in blistering and scarring of the skin. The 
presence of varying shades of foci of pallor indicates deep partial 
thickness burns that heal within six weeks. However, healing may 
be incomplete. These burns scar the skin and frequently require 
grafting Surgical Full thickness burns result in injury and loss of 
the entire epithelium and dermis (third degree). A full thickness 
burn may also involve injury to underlying structures such as 
muscles, nerves, tendons, or bones (fourth degree). If left on their 
own, without surgical intervention, these burns would take well in 
excess of six weeks, or even months, to heal. These burns may 
cause significant scarring and, if present around joints, may 
severely limit the range of motion. 
First degree - superficial (erythema) Second degree - deep 
(blister, pallor) Third degree - white, tan, beige, red, etc. skin color 
Fourth degree - involves tendon, bone, etc.  
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Burn injuries may also be classified according to the type of 
noxious agent causing the burn (e.g., flame, scald, flash, contact, 
smoke inhalation, electrical). Scald injuries, the most common burn 
injury in civilian populations, are secondary to contact with hot 
liquids. Hot water is the most common cause of scald injury, but 
other agents can include coffee, tea, soup, sauces, hot grease, or oil. 
Burns secondary to contact with tar and asphalt are also 
considered scald injuries. 
Flame burns are secondary to contact with a source of open 
flame. House fires, careless smoking, automobile accidents, 
inappropriate use of flammable materials, and ignition of clothing 
are common factors associated with flame burn injury. Flame burns 
are associated with a serious and potentially fatal condition known 
as smoke inhalation injury. Inhalation injury is due to the exposure 
of the respiratory tract to steam and toxic inhalants from the 
smoke of a fire. 
Flash burns are secondary to exposure to explosions of 
combustible or flammable materials. Contact burns are secondary 
to skin contact with hot items such as metal, glass, chemicals, 
plastic, or coals. Electrical burns are thermal injuries that occur 
when electrical energy is converted into heat upon contact with the 
skin. Electrical burns can severely affect deeper structures such as 
nerves or bones even when there is minimal damage to the 
overlying skin.  
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Burn Care 
In the past three decades, burn care has undergone 
significant transformation, and this has led to markedly improved 
survivability. The health care system has developed a sophisticated 
approach to hospital burn care that is predicated on a network of 
specialized burn treatment centers. These centers are well 
equipped and professionally staffed to treat local injuries and to 
handle the transfer and treatment of serious burn injuries from 
more distant locales. This transformation of burn care reflects 
advancements in multiple areas of medicine, including critical care, 
wound infection control and antimicrobial therapy, surgical therapy 
(e.g., early excision and grafting), specialized burn care research, 
and coordinated methods of burn patient transfer (e.g., air 
ambulance and accompanying medical support services). Early 
excisional therapy of deep partial thickness or full thickness burns 
is common Burns that heal within three weeks commonly do well 
and are less likely to produce hypertrophic scarring or functional 
impairment. Burns that require more than three weeks to heal are 
commonly associated with hypertrophic scarring or functional 
impairment. For patients with small to moderate burn injuries 
where the healing time will exceed three weeks, early excision and 
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grafting is the recommended course of treatment. The benefits of 
early excision and grafting include decreased hospitalization, early 
return to work or school, enhanced functional status, and improved 
physical appearance. However, properly estimating the time to 
healing for a burn remains an important clinical challenge. Risk 
factors associated with mortality in burn injury include total body 
surface area (TBSA) greater than 40 percent, age over 60 years, 
and inhalation injury. Temporary or permanent disabilities are 
common in patients with significant burn injuries who are admitted 
to specialized burn care facilities. Reconstructive surgery and long-
term rehabilitation are routine components of extended care for 
disabled burn patients. 
Psychosocial Aspects of Burn Injury 
The morbidity associated with burn injury is not limited to 
physical conditions such as pain or scarring. Psychiatric and 
psychosocial morbidities form important and often overlooked 
aspects of burn injury. Psychiatric and psychosocial morbidities are 
classified into pre- and post injury conditions. Pre-injury 
psychiatric conditions in adults may include depression, suicidality, 
substance abuse, and personality disorders. In children, pre-injury 
conditions may include behavioral disorders such as conduct 
disorder or attention deficit hyperactivity disorder. 
 21
In the post-injury phase, hospitalization and acute burn care 
can lead to psychiatric and psychosocial stresses for patients. 
Common psychiatric conditions include delirium, acute stress 
disorder (ASD), post-traumatic stress disorder (PTSD), and 
depression. Psychological suffering (i.e., PTSD) may also be 
manifest in the parents of children or adolescents with burn injury. 
The first year post-burn injury may be particularly 
psychologically stressful for patients, but most adult and pediatric 
burn patients do not suffer long-term, burn-related, psychiatric 
sequelae. For a minority of burn injured patients, altered patterns 
of socialization may develop, especially for men with visible 
disfigurement. In women, decreased levels of sexual satisfaction are 
a frequent long-term result of burn injury. 
Outcomes. Studies with the following outcomes could be included: 
1. Need for surgical procedure (e.g., grafting, debridement, 
fasciotomy, quality of graft take [percentage], re-grafting, 
reconstructive surgery); 
2. Pain; 
3. Transfusion rate; 
4. Mortality (prior to, or after, discharge from hospital); 
5. Length of stay in hospital; 
6. Scarring (size, hypertrophic scarring); 
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7. Decrease in range of motion, function, or activities of daily 
living; 
8. Respiratory measures (e.g., length of intubation); 
9. Thrombosis and emboli; 
10. Complications (e.g., bleeding, infection); 
11. Rehabilitation; 
12. Quality of life; and 
13. Psychiatric adjustment (e.g., PTSD, anxiety, depression). 
Three of the articles were randomized controlled trials 
(RCTs) in adult and pediatric burn patients. The first, by 
Srivastava et al., was a comparison of heparin and standard 
therapy to standard therapy alone. Heparin use was found to 
improve the following outcomes, mortality, infection rate, graft 
healing, and eschar separation. For mortality, three out of 25 
people died in the heparin group, while 11 out of 25 people died in 
the control group. Infection rates were lower in the heparin group, 
with 20 people having wound infection versus all 25 people in the 
control group. Grafts healed 11 days faster on average in the 
heparin group and eschar separation was a mean of 9 days faster in 
the heparin group. The study had a clear monitoring protocol for 
adverse effects and no increases in bleeding were found as a result 
of heparin use. Lastly, the treatment regimen was a combination of 
systemic and topical heparins, so any potential therapeutic benefits 
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could not be attributed to one route of administration over the 
other. 
Another RCT showed that topical heparin significantly 
reduced primary scarring in 37 heparin-treated adults and 
children. These people were compared to 27 controls who received 
standard therapy. However, the method of treatment allocation 
was not described in the publication and the outcome measures 
were not validated in burned patients. Thus, it is difficult to 
attribute the favorable outcome to heparin alone.  
In a recent study by Venkatachalapathy et al., was conducted 
to examine the effect of topical heparin on clinical outcomes in 
people with second degree burns (age range:15 to 35 years). Control 
patients received usual treatment, which included topical 
antimicrobial cream, debridements, and skin graftings in the early 
post-burn period. Outcomes included length of hospital stay, 
mortality, and number of skin grafts. The authors found a 
significantly (p<0.001) shorter length of hospital stay in the 
heparin-treated patients (all 50 heparin-treated patients had 
lengths of stay about 40 days, while 28 of 50 control patients had 
stays of 40 to 50 days). There was also less mortality (0 heparin 
versus 5 controls) and fewer skin grafts (4 heparin versus 10 
controls) in the heparin group. Two articles contained 
investigations of heparin’s use in adult-only burn populations. The 
first, by Reyes et al., was a non-randomized, comparative (cohort) 
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study of nine patients who were injured in a thermal disaster. Four 
patients received topical heparin immediately after hospital 
admission and they were reported to have better pain relief, less 
swelling, fewer fasciectomies, a shorter length of hospital stay, and 
earlier burn revascularization than five control patients who did 
not receive topical heparin until 5 days after hospitalization. 
While the results were positive for heparin, they must be 
interpreted. The other article about heparin use in adult burn 
patients was written by Acharya, who compared the effects of three 
therapies: 1) topical heparin, 2) topical heparin with topical steroid 
and antibiotic, and 3) topical steroid and antibiotic alone. The study 
showed no difference between treatment groups. Three studies 
focused on the use of heparin to treat burns in pediatric 
populations. Desai et al. conducted a non-randomized trial (cohort 
study) to examine the effect of aerosolized heparin with 
acetylcysteine for 7 days on inhalational burn injuries in children. 
The heparin/acetylcysteine group (n = 47) had significantly less 
reintubations, less atelectasis, and a lower mortality rate than the 
standard therapy group (n = 43, p < 0.05). A pediatric article was 
an unpublished cohort study to compare nine children undergoing 
standard burn therapy in 1998 to 10 children undergoing standard 
therapy plus heparin (intravenous followed by topical) in 1999. The 
authors measured pain using subjective, observational criteria like 
patient behavior (e.g., crying, struggling) and a decrease in the 
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“noisy din and distressing emotional ambience” of the hospital 
ward. These observations were not measured in a systematic, 
quantitative fashion and therefore should not be taken as 
indicative of a treatment effect. 
Given the above review, some of the abstracted studies 
contain evidence that heparin has potential clinical benefits in the 
areas of reducing mortality, reducing pain, improving cosmesis, and 
alleviating lung injury in inhalational burns. However, these 
studies suffer from some limitations. In light of these limitations, 
the evidence supporting the use of heparin in burn injury cannot be 
considered strong and has to be investigated by RCTS. 
There are insufficient data available to determine if the 
method of application of heparin in burn patients makes a 
difference with respect to clinical outcomes. 
The following gaps exist within the literature. Four published 
studies and two unpublished manuscripts comparatively examined 
(e.g., treatment versus control) clinical outcomes in the use of 
heparin to treat burns. Another study had clinical outcomes, but 
the effect of heparin could not be separated from concomitant 
therapy. In these studies, no comparisons were made of systemic 
heparin (intravenous or subcutaneous) or topical heparin 
applications to the burn site. 
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There are insufficient data available to evaluate the outcome 
of treatment with heparin in Burns that vary by type of degree of 
Burn. 
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Outcomes of burn treatment with heparin compare to 
current treatment without heparin 
Multiple roles for heparin in the treatment of burns were 
examined in the abstracted studies. These roles included wound 
healing and pain control, as well as the treatment of sepsis, 
inhalation injury, and venous thrombosis. However, there were 
insufficient data available to answer the key question. This was 
because the abstracted studies were conducted in eight different 
countries with varying standards of burn care and published over a 
time span of three decades. Thus, the studies simply did not 
encompass any standard, current burn treatment.  
In addition, nine abstracted studies were primarily 
laboratory studies without clinical outcomes. Four of the abstracted 
articles specifically addressed the issue of contraindications to the 
use of heparin in burn patients. This was limited to listing 
contraindications for subcutaneous or intravenous applications of 
heparin such as bleeding diathesis, bleeding history, active 
bleeding or associated trauma with potential bleeding, active 
intestinal ulcer, thrombocytopenia, liver disease, renal disorders, or 
allergy to heparin. The authors of two articles wrote that these 
contraindications were exclusion criteria, while the authors of the 
other two articles wrote that none of the patients in their studies 
had any of these contraindications. 
 28
When using heparin in burn patients, it would be prudent to 
apply the same precautions as would be applied to the use of 
heparin in patients with thromboembolic disease. The most 
common contraindication for heparin in patients with 
thromboembolic disease is bleeding. The risk of bleeding increases 
with higher heparin doses and is associated with patients’ 
anticoagulant responses, the method of heparin administration, the 
co-administration of anti-platelet or fibrinolytic agents, and recent 
trauma or surgery. Bleeding is as frequent with low molecular 
weight heparins (LMWHs) as with unfractionated heparin (UFH). 
In one study, bleeding was observed in 5.2 percent of patients who 
were given continuous intravenous heparin and in 4.1 percent of 
patients who were given subcutaneous heparin. Both groups 
received approximately the same mean dose over 24 hours. 
Heparin can cause thrombocytopenia and is therefore 
contraindicated in patients who have had recent surgery (primarily 
for venous problems) or pre-existing cardiovascular disease 
primarily arterial). The incidence of thrombocytopenia was 
reported to be 0.3 percent in patients treated with heparin 
prophylaxis and 2.4 percent in patients treated with heparin 
therapeutically. Heparin-induced thrombocytopenia is an antibody-
mediated process that can lead to arterial or venous thrombosis. 
The estimated incidence of vertebral fractures in people receiving 
long-term UFH therapy is three out of 100. Approximately 30 out of 
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100 people who receive therapeutic doses of heparin for longer than 
one month will experience reduced bone density that can lead to 
osteopenia or osteoporosis. The risk of osteoporosis was observed in 
groups of patients who had received long-term heparin therapy (> 6 
months) at doses greater than 15,000 anti-Xa units. Much of the 
research on heparin and osteoporosis has been confined to pregnant 
women, so prolonged heparin use is contraindicated in this group. 
Osteoporosis is less common with LMWHs than with UFH. 
Much of the available evidence regarding contraindications to 
heparin concerns subcutaneous or intravenous applications of the 
substance. In some of the abstracted articles, heparin was applied 
topically and there is no information regarding the 
contraindications of heparin when administered by this route. 
Reported adverse effects of heparin in treating burns. 
Srivastava et al. reported a clear monitoring protocol for 
adverse effects (in their case, bleeding) and they did not find any 
increases in bleeding secondary to heparin use. Two other articles 
contained reports of bleeding in heparin-treated patients. The 
incidence of bleeding was low when reported. One heparin-treated 
patient in a pediatric study (n = 19) bled on the burn surface. In  
another study (n = 9), three patients who received topical heparin 
beginning on the fifth day of hospital admission developed bleeding 
on day 8 of the study. However, the authors attribute the bleeding 
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to a treatment error: the dose of heparin was not reduced following 
burn revascularization. The bleeding may have been avoided if 
heparin was titrated properly. 
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HEPARIN TREATMENT REGIMENS AND RESULTS 
Author Type of Heparin 
Method of 
Herparin 
Administration 
Heparin 
Treatment 
Regimen 
Outcomes Results 
Adverse 
Effects 
Heparin 
Acharya Hirudodi 
Anticoagulant 
(100 g) 
equivalent to 
25,000 units of 
heparin) 
Topical NR 1)  Pain relief (relief 
within 5 minutes to 3 
hours) 
2) Healed (Reductino 
of the burned or 
inflamed surface by 
≥50% within 3 days) 
1) Hirudoid cream 
group : 27/36 pain 
relief and 19/36 
healed 
2) Anacal ointment 
group : 16/16 pain 
relief and 4/16 healed 
3) Antibiotic group : 
24/33 pain relief and 
16/33 healed 
NR 
Curreri et 
al. 
NR Subcutaneous 5,000 units Fibrin split – product 
concentration 
No quantitative data 
reported in the 
published article  
NR 
Desai et al. NR Aerosolized 5,000 units of  
aerosolized heparin 
alternating  with 3 
ml of a 20% solution 
of  acetylcystine, 
every 2 hours for 
the first 7 days 
after injury 
1) Reintubation 
2) Atelactsis 
3) Mortality 
1) Reintubation : 
heparin group 3/47, 
control group 12/43 
2) Atelactasis : 
heparin group 20/47, 
control group 30/43 
3) Mortality : heparin 
group 2/47, control 
group 8/43 
NR 
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Author Type of Heparin 
Method of 
Herparin 
Administration 
Heparin 
Treatment 
Regimen 
Outcomes Results 
Adverse 
Effects 
Heparin 
lashvili et 
al. 
NR Subcutaneous 6,000 units  in the 3 
groups treated with 
heparin 
1) Changes in the 
gastyrointestinal 
mucosa (e.g., ulcers, 
erosions, and 
hemorrhages)  
2) Separation of the 
burn eschar  
3) Time between 
burning and 
development of he 
wound surface ready 
for auto grafting 
4) The period of 
treatment between 
burning and complete 
healing 
1) Changes in the 
gastrointestinal 
mucosa : control 
group 12/20, group 4 
(complete therapeutic 
regiment) 7/20  
2) Separation of the 
burn eschar : 7-9 days 
faster in group 4 
3) Time between 
burning and 
development of the 
wound surface ready 
for auto grafting : 
44% shorter in group 
IV 
4) The period of 
treatment between 
burning and complete 
healing : REduced 30 
days in group 4 
NR 
Khadzhiiski 
et al. 
Heparin 
(cream and 
dressing) 
Topical 5,000 IU Cicatrisation Significant reduction 
in primary 
cicatrisation in 37 
treated children and 
adults compared to 27 
controls 
NR 
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Author Type of Heparin 
Method of 
Herparin 
Administration 
Heparin 
Treatment 
Regimen 
Outcomes Results 
Adverse 
Effects 
Heparin 
Kuz’muk et 
al. 
NR NR NR 1) Prothrombin 
activity  
2) Thrombotest value 
3) plasma 
recalcification time 
4) Plasma tolerance to 
heparin 
5) Fibrinogen 
concentration 
No quantitative data 
reported in the 
published article 
NR 
Loebl et al. NR Subcutaneous 20,000 units in four 
divided doses 
Autologous half-life of 
erythrocytes 
No quantitative data 
reported in the 
published article 
NR 
Mariano et 
al. 
NR Continous 
infusion 
Heparin +  
CPFA as renal 
replacement 
therapy 
1) Blood flow 
2) Used 
Cartridges/session 
3) Blood iCa 
4) Blood pH and 
bicarbonates 
No quantitative data 
reported in the 
published article 
NR 
Mims et al. Beef lung and 
intestinal 
mucosal 
 NR Heparin not used 
for treatment 
(heparin was used 
as a reagent) 
Platelet aggregation In contrast to 
controls, 15% of blood 
samples from burn 
patients  
demonstrated 
spontaneous 
aggregation, and 69% 
showed either first or 
second phase 
NR 
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Author Type of Heparin 
Method of 
Herparin 
Administration 
Heparin 
Treatment 
Regimen 
Outcomes Results 
Adverse 
Effects 
Heparin 
aggregation after 
exposure to heparin 
Ono et al. NR Infusion 10,000 – 20,000 IU 
daily 
1) Platelet counts 
2) Finrinogen levels  
3) Plasminogen levels  
4) Fibrin degradation 
product levels 
No quantitative data 
reported in the 
published article 
NR 
Peng et al. Heparin and 
low molecular 
weight heparin 
Intravenous 100 – 1,500 units 1) Median stay in ICU 
2) Total days in 
hospital 
3) Mortality 
No quantitative data 
reported in the 
published articles 
No heparin – 
related 
adverse 
effects 
observed 
Reyes et al. 
2001 
NR Infusion, 
subcutanesou, 
sprayed or 
dripped via 
needle, 
aerosolized 
1st applicaiton was 
5,000 IU/ml dripped 
or sprayed on open 
burn surfaces or 
injected into burn 
blisters – 
retreatment at 5 – 
10 minute intervals 
for 20 – 30 minutes 
1) Mean doses of pain 
medication 
2) Swelling 
3) Fasciectomy  
4) Burn 
revascularization 
1) Mean doses of pain 
medicaiton: heparin 
group (received 
heparin day 1) = 4 
doses, control group 
(received heparin day 
and 5 and later ) = 24 
doses 
2) Patients given 
heparin on day 1 had 
less burn swelling 
and body swelling, 
and no fasciectomies, 
compared to patients 
given heparin on day 
Bleeding  
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Author Type of Heparin 
Method of 
Herparin 
Administration 
Heparin 
Treatment 
Regimen 
Outcomes Results 
Adverse 
Effects 
Heparin 
5 
3) Burn 
revasularization was 
faster in patients 
given heparin on day 
1 
Srivastava 
et al. 
NR Topical and 
systemic 
1) Systemic route : 
10,000 units 10% 
burn area, repeated 
every 4-6 hours; 
increased to 
maximum 300 – 
400 units / 15% 
burn / kilogram 
body weight 
2) Topical 
application ; 25,000 
units / 10% burn 
1) Mortality 
2) Mean healing time 
3) Full thickness 
Eschar separation 
4) Raw area fit for 
grafting 
5) Graft take 
1) mortality : heparin 
group 3/25, control 
group 11/15 
2) Mean healing time 
: heparin group 6 days 
(superficial) and 15 
days (deep dermal), 
control group 10 days 
(superficial) and 28 
days (deep dermal) 
3) Eschar separation : 
heparin group 20 
days, control group 36 
days 
5) Graft take : 
heparin group 95% 
control group 65% 
No observed 
bleeding 
Venkata-
tachala – 
pathy et al. 
Heparin 
sodium 
solution 
(boving 
Dripped onto 
buirn surfaces or 
injected into 
burn blisters 
200 IU/ml 1) Mortality 
2) Days in hospital 
3) Number of skin 
grafts 
1) Mortality : heparin 
group 0/50, control 
group 5/50 
2) Days in hospital : 
NR 
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Author Type of Heparin 
Method of 
Herparin 
Administration 
Heparin 
Treatment 
Regimen 
Outcomes Results 
Adverse 
Effects 
Heparin 
intesinal 
mucosa) 
heparin group had 29 
patients discharged in 
≤ 10 days, control 
group had 3 patients 
discharged in ≤ 10 
days 
3) Number of skin 
grafts : heparin group 
4/50, control group 
10/50 
Wahl et al . 
(a) (b) 
Low molecular 
weight heparin  
(enoxaparin) 
Subcutaneous 40 units 4x/day Development of upper 
or lower extermity 
DVT or pulmonary 
embolism 
7 patients had DVT (1 
patient had upper 
extermity DVT and 2 
patients had both 
upper and lower 
extermity DVT). 6 
patient had 
superficial vein 
thrombosis (SVT) in 
the upper extremities. 
NR 
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Study outcomes: A variety of clinical outcomes should be 
considered for the next generation of studies on heparin and burns. 
The outcomes would vary slightly depending on whether adult or 
pediatric populations are studied. Some of these outcomes are: 
1. Mortality 
2. Incidence of medical procedures following initial treatment 
with heparin or standard therapy (e.g., reintubation, excision, 
grafting); 
3. Pain (measured using the McGill Pain Scale) 
4. Scarring (measured using the Vancouver Scar Scale) 
5. Itching (measured via the amount of anti-pruritic 
medications used [e.g., Pedichloryl®]) 
6. Quality of Life (measured using the Health Outcomes Burn 
Questionnaire for children and the Burn-Specific Health 
Scale100 for adults); and 
7. Post-traumatic Stress Disorder (measured using the Child 
Stress Disorders Checklist101 for children and a selected 
range of measurement methodologies for adults). 
Studies that are designed with the above precepts in mind 
will overcome the pitfalls of the abstracted articles and provide the 
clinical community with a clearer picture of the efficacy of the 
various uses of heparin in the treatment of burns. 
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MATERIAL AND METHODS 
Place of study 
 The study was done at Department of Burns and Plastic 
surgery, Govt.  Kilpauk Medical College, Chennai – 600 010. 
Duration of Study 
 In the period between Jan 2005 to Jan 2006. Forty patients, 
with adults and children with second degree burns and scalds with 
TBSA burn 7% to 25% were recruited at random. They were 
allotted in to 3 separate treatment groups. Group A patients 
numbering 10 were treated with topical heparin in addition to the 
standard protocol burns management. The group B patients 
numbering 10 were treated with Healicoll™ (a Type I Collagen 
sheet preparation). 
 Group C had 10 patients with symmetrical burns on either 
side who served as their own control with Heparin on one side and 
Collagen applied on other side.Thus making 20 burn wounds 
treatment with heparin and the other 20 burn wound treated with 
Type1 collagen. 
Inclusion Criteria  
1. TBSA burns size from 5% to 25%. 
2. Partial Thickness (second degree) Burns. 
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3. Age from 1 year to 60 years. 
4. Flame burns, scalds, steam burns were included. 
Exclusion Criteria 
1. Burns with TBSA more than 25%. 
2. Patients aged more than 60 or less than 1 year . 
3. Electric Burn. 
4. I degree and full thickness burns. 
General treatment of Group A & Group B 
 All the 40 patients enrolled were initially assessed at arrival 
for the estimation of TBSA size. For calculating the TBSA, the 
Lund and Browder chart was used. The degree of the burns was 
assessed clinically. Rapid physical examination of vital signs, 
mental status, adequacy of lung air entry were done. 
 The superficial second degree burn were diagnosed based on 
clinical ground by the presence of  
1. Red Appearance 
2. Blisters 
3. Blanching on finger pressure. 
4. Intact tactile & pressure sensation 
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 The second degree deep burns were recognized by the dry, 
mottled wound appearance and failure to blanch under digital 
pressure. All the patients had immediate intravenous lines secured 
with 18G large bore canula. Emergency sedation with Pedichloyl 
for paediatric patient and with Inj. Pentazocine with Promethazine 
was administered to adult. Prophylactic tetanus toxoid was 
routinely administered. Systemic antibiotics was given to all the 
patients according to the antibiotic policy of the department, which 
consisted rotation of empirically administered antibiotics based on 
the monthly antibiogram audit report of the preceding month, 
which included either single or combination of Ampicillin, 
Gentamycin, Amikacin, Cefotaxime, Cerftriaxone and Metrogyl in 
the standard dosages. These patients were neither catheterized nor 
had Ryles tube insertion. Emergency base line investigation for 
estimation of haemoglobin, hematocrit, RFT, and electrolytes were 
done wound swab was not done on the day of admission. 
 Modified Parkland formula (3 x TBSA x wt in kg) was used to 
calculate the IV fluid requirement for both adult and paediatric 
subset with 10% TBSA burn on more. 
 To avoid any confounding effect due to intravenous heparin 
on the outcome, both the group A & B & C were not administered 
intravenous heparin, which otherwise is the standard protocol 
followed in the department. 
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Local treatment of Group A 
 Under mild sedation, the local debridement of the wound was 
done routinely in bed side. The blisters were routinely removed by 
mechanical cleaning of skin. The wound washed with 5% povidone 
iodine with saline. Heparin sodium IP in the concentration of  
5000 IU/ml was sprayed over the cleaned wound with 10cc syringe 
and 25G needle. The topical heparin dose was calculated with the 
formula 5000 IU x TBSA / day. Half of the calculated dose was 
sprayed over the wound and the remaining was diluted with saline 
and gauze pieces soaked in this heparin saline were used to cover 
the burn wound. Surgical pads were not used and heparin saline 
gauze dressing covered with bandages. The dressing was changed 
the next day and same amount of heparin was used till wound 
epithelialised. 
Local treatment of Group B 
 Under mild sedation, the local debridement of the wound was 
done routinely bedside. The blisters were removed. Mechanical 
cleaning of skin done in the same way, wound cleared with 5% 
povidone and saline. A collagen based sterile wound dressing 
HealicollTM (containing sterile reconstituted Type I collagen sheet, 
a semi-occlusive and would adhesive dressing (Advanced biotech 
production (P) Ltd., India) was applied to the wound. The collages 
sheet was put in saline for a few seconds for easy application and 
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was not necessarily rinsed thoroughly as it did not contain any 
irritant preservatives. The spread collagen sheets were allowed to 
dry in room air and temperature for few hours till wound adherence 
was complete. 
Local treatment of Group C 
 These patients selected when they had symmetric 
distribution of burns on either side of the body so that they served 
as their own control on one side treated with Heparin and the other 
side treated with Type I Collagen sheet (Healicoll TM)  
Measurement of outcome 
 Complete epithelialisation was certified by a senior faculty. 
The patients with Healicoll group B were discharged in a day and 
were asked to come for review and alternate days to the OPD. 
Group A patients on Heparin topical therapy were usually treated 
as inpatients till complete epithelialisaiton since they needed daily 
dressing. 
(1) Healing time 
 Complete epithelialisation was certified by either the chief of 
the department or a senior faculty and the same was noted. 
(2) Patient comfort 
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(a) Pain : The pain was subjectively recorded as stated by the 
patients in a visual analog pain scale of 1 – 10. The pain scale 
reading was taken on the day 2 and day 4 and the average was 
recorded. 
(b) Itching : The itching was graded into mild moderate or severe 
and the subjective description of the patient was recorded at the 
time of complete would epithelialisation. 
(3) Length of stay in hospital and mortality rates were recorded 
from case records. 
(4) Scar assessment 
 The patients scar was assessed at the time of complete 
epithelialisation and at 2 months. The patients were communicated 
by post at the end of 6 months to report to the burns unit for scar 
assessment. 
 The scar assessment was objectively recorded using he 
Vancouver scar scale. 
Vancouver Scar Scale 
 I Pigmentation 
   grade 0   ( Normal colour) 
   grade 1   (Hypopigmentation)   
   grade 2   (Hyperpigmentation) 
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II Scar Thickness  
grade 0 ( Normal) 
grade1 (less than 2 mm) 
grade2 ( 2 to 5 mm) 
grade3 ( more than 5 mm) 
III Itching 
Grade1 (mild) 
Grade2 (moderate) 
Grade3 ( severe) 
IV Scar texture 
grade 0 ( Normal) 
grade1 ( supple) 
grade2 ( yielding)  
grade3 ( firm) 
grade4 ( banding but no limitation of ROM) 
grade5 ( Contracture) 
 To avoid observer variation, the scar assessment with the 
above criteria were done by same observer and recorded in the 
proforma. The observer was in unaware of the primary treatment 
modality of the burn wound to avoid bias. 
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RESULTS 
I AGE 
Children Adults 
19 11 
 Superficial second degree burns for the study were 
contributed by 66% paediatric patients defined as age below 12 
years. 
II PERCENTAGE OF BURNS 
TBSA Children Adult 
Upto 8% 8 2 
9 – 16% 7 4 
17 – 25% 4 5 
 Of the above patients wherever the patient had symmetrical 
distribution on either side, the patients formed their own control 
group by application of heparin on one side and Type II Collagen 
Healicol on the other side. (n = 10). 
III CAUSE OF BURNS 
 Scalds Flame burn 
Children 16 3 
Adults 6 5 
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Majority of the study group consisted of accidental scalds in 
children (72% were scalds). 
IV TIME TAKEN FOR EPITHELIALISATION 
 Heparin Collagen 
7 – 8 days 1 - 
9 – 10 days 10 6 
11 – 12 days 5 9 
13 – 14 days 3  5 
15 – 16 days - - 
17 – 18 days 1 - 
 It was noticed that heparin group epithelialised faster as the 
collagen group took more time to get separated. Two patients on 
topical heparin who developed mild wound infection took more time 
to heal. 
V PAIN, COMPLICATIONS AND MORTALITY 
 Heparin Collagen 
Wound infection 2 - 
Bleeding - - 
Sensitivity reactions - - 
Mortality 0 0 
Pain estimate by analog visual scale 3.2 4.8 
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 No case of bleeding was noted with 5000 IU/ml concentration 
of topical heparin. Type I collagen sheet remarkably had no 
infective complications. Heparin group patients were more 
cooperative for mobilisation due to less pain as against the collagen 
group who experienced pain and stiffness due to collagen drying up. 
VI ITCHING ON COMPLETE EPITHELIALISATION 
 Heparin Collagen 
Mild - 3 
Moderate - 1 
Severe - - 
Collagen group needed mild doses of chlorpheniramine 
maleate to alleviate mild pruritus. About 20% of collagen 
applicated wounds experienced mild itching at some point of time. 
VII SCAR COLOUR ASSESSMENT AT 2 MONTHS 
Color of the Scar Heparin Collagen 
Grade 0 2 0 
Grade 1 (pink) 16 10 
Grade 2 (Red) 2 9 
Grade 3 (Purple) 0 1 
 Pink colour represented good scar. Red and purple scars were 
adviced compression garments to avoid Hypertrophic scar. 
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VIII REQUIREMENT OF OTHER SURGICAL 
 PROCEDURES 
 Only superficial second degree burns were consciously 
selected for the study. In both group complete epithelialisation was 
observed sooner or later and none in the study group needed 
grafting nor any other surgical procedures like escharatomy. 
IX VANCOUVER SCAR SCALE ASSESSMENT AT 6 
 MONTHS 
Pigmentation Heparin Collagen 
Grade 0 near normal 11 1 
Grade 1 (Hypo pigmentation) 9 18 
Grade 2 (Hyper pigmentation) - 1 
 Collagen group healed with significant hypopigmentation 
(59%), though not complained by the patients themselves. 
B 
Scar Thickness Heparin Collagen 
Grade 0  16 8 
Grade 1 < 2mm 3 8 
Grade 2  - 2 – 5mm 1 3 
Grade 3 > 5mm 0 1 
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              63% applications of heparin healed with good scar 
thickness defined as grade 0 or grade 1 as against 52.8% good scar 
thickness in Type I collagen. 
Scar Texture Heparin Collagen 
Grade 0  9 5 
Grade 1 supple 9 8 
Grade 2  yielding 2 3 
Grade 3  firm - 4 
Grade 4 Binding / Blanching - - 
Grade 5 contracture - - 
 Clinical palpation methods showed smoother and supple 
scars with heparin group. Palpable roughness was noticed in the 
collagen group healing, though no overt banding nor contractures 
in either group. 
D ITCHING AT 6 MONTHS 
 Heparin Collagen 
Grade 0 20 17 
Grade 1 - 3 
Grade 2 - - 
Grade 3 - - 
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              9% of the wounds in collagen group had mild itching at 6 
months which required seasonal medication. No itching noted with 
heparin. 
X SCAR ASSESSMENT BY THE PATIENT / OR / 
 RELATIVES 
 Heparin Collagen 
Good 18 17 
Satisfactory 2 3 
Poor - - 
               Though there were perceptible minor differences in scar, 
suppleness, texture and pigmentation, the patients, themselves 
were happy about the outcome with 90% of heparin group and 88% 
of collagen group reporting their scar as ‘good’. 
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DISCUSSION 
 Though both collagen as biological dressing and topical 
heparin have been validated in the management of partial 
thickness burns, no randomized control study have been done to 
evaluate the supremacy one over the other. Comparisons have been 
done with subjects taken during deficit times and of different age 
groups with similar burns. However, the assessment of partial 
thickness burn as superficial or deep is mostly by clinical methods 
and are open to observer variation. 
 In this study topical heparin is used as once a day application 
as partly as spray and partly as heparin impregnated gauze 
dressing, after debriding the burn blisters. Saliba et al and few 
other burn centers have used heparin in the concentration of 5000 
IU/ml. In a study by Mohankumar et al from Pondicherry, Heparin 
was used in the concentration of 200 IU/ml by adding 20.8 ml of 
Heparin to 500ml of NS and same sued as a continuous drip 
irrigation. The investigation have not debrided burn blisters but 
have irrigated the blisters and allowed the blister skin to remain as 
a desiring. 
 This study had more of scalds (73%) and 63% of the subject 
were of pediatric age group. It was noted that 80% of pediatric burn 
were due to accidental scalds. 
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 On topical spraying of heparin sodium IP in the concentration 
of 5000 IU/ml, at an average dosage of 5000 units per percent of 
burnt area (1ml per 1% burn) the patients experienced a mild 
burning sensation for 2 – 3 seconds which was followed by 
immediate pain relief. The paediatric age group patients could get 
rid of the apprehension are they could experience the pain relief. 
 For smaller area of burn less than 10% TBSA, though the 
hospital policy is to treat on outpatient basis, the patients of the 
heparin study group had to be admitted to make convenient the 
daily dressing charges. Whereas the collagen group of patients were 
routinely discharged after few hours after the collagen dried up or 
the next day. 
 2 Cases of minor wound infection was noticed in the heparin 
group as against no such infection in collage group. This is 
understandable  due to the large load of burn patients with varying 
septic load being managed in the common ward and considering the 
non occlusive nature of during with topical heparin. The infection 
in the 2 cases leads to delayed wound epithelialisation in them by 5 
days. 
 In the 10 patients in group C who was treated with either 
form of dressing on either half served as their own controls. It was 
well noticed that the ability and ease of functional mobilisation and 
joint stretching manouvers by the physiotherapy team was easier 
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and had good patient co operation in the sides where heparin was 
used. The collagen on drying up created a feeling of ‘catching up the 
skin’ on attempted mobilisation and co operation for functional 
mobilisation with collage was visibly less. 
 The change of dressing daily with the topical heparin was a 
substantial discomfort to the patient on the heparin soaked gauze 
drying up and stuck to wound and was painful while changing. The 
daily dressing was an ordeal for the patient as it is not possible in a 
large burn care centre as ours to give adequate sedation for daily 
dressing changes and the time to be allotted to the patient for daily 
dressing change by the surgeon was more. These two factors are a 
definite disadvantage with topical heparin therapy. 
 The collagen stuck to the wound and even after 
epithelialisation some fragments were skill stuck to the healed 
wound and gave the impression of more time for epithelialisation. 
 A Substantial percentage of 20% with collagen experienced 
pruritus at time of complete wound healing and for months after 
complete wound healing. The reconstituted collagen might have 
caused more aggregative of mast cells causing itching. But the 
itching persisted for months and the reason for the prolonged 
sensation of itching has to be studied further and remedied. 
 The Vancouver scar scale was specifically introduced for the 
burn wound in 1991. 
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 The parameters like color and pigmentation are observer 
dependent and hence they were done by the same observer who was 
a senior faculty member of the centre. The more recent methods of 
scar assessment by volumetry or ultrasanography are not available 
and not practical. The thickness of the scar was measured by 
clinical means by palpation and no special techniques like 
photothesiometry were used. 
 The scar outcome at 2 months and again at 6 months were 
favourable with the heparin group, with no itching attack. There 
were small difference in the texture of the collagen group and 
heparin group. Though they were of academic importance the 
patient was happy with the outcome on either group and they rated 
than scar outcome as good. Most of the patients were not worried 
about minor pigmentary variations of the healed skin, even when 
in exposed parts of the body. 
 In superficial second degree burns (mostly scalds)the collagen 
application notably had left a healed wound with marked 
hypopigmentation at 6 months. The behaviour of this healed ulcer 
beyond 6 months needs to be studied further. 
          The cost of dressing material needed for a 5 percent burn 
wound in an average adult with Healicoll Type 1 collagen sheet 
worked to Rs.1800. The cost of Heparin for treating similar percent 
burns worked to Rs.450. But this may be an over simplification as 
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the repeated dressing time, the saline, the dressing gauze material 
and technical man hours , the significant hospital stay with 
heparin treatment are all to be taken in to account and thse 
parameters can not be quantified. But it was commonly noticed 
during the study that patients and their attenders wished to get 
out of hospital sooner but had to be retained for the sake of daily 
dressings, whereas the collagen group patients were discharged in 
a day or 2 . Hence the cost of the total treatment can not be 
confused with the cost of dressing material only. The hidden costs 
and discomforts are far greater with the heparin treatment group. 
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CONCLUSION 
1. Topical Heparin in concentration of 5000 IU/ml per percent 
TBSA burns per day is safe and has no bleeding 
complications and needs no monitoring by BT, CT or PTT. 
2. The final scar outcome with parameters such as scar 
itchiness, texture and pigmentation are favourable with 
topical heparin therapy. However the patient’s satisfaction 
level are same for both groups.  
3. The wound infection rate is less with collagen sheet dressing 
when compared to topical heparin. 
4. Hospitalization and patient discomfort, technical labour 
required are all significantly high with topical heparin. 
May be concluded that Type I collagen sheet dressing is 
preferable to heparin dressing in a large burn centre such as KMC 
in view of faster patient turnover, lower infection rate, ease of 
management and single application time, significantly reduced 
hospital stay and comparable patient satisfaction level of final scar 
outcome. 
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PROFORMA 
Burn wound healing heparin vs collagen  
1. Name    Age :   Sex : 
2. Address :    IP No. : 
      DOA : 
      DOD : 
3. TBSA % Burn 
4. Occupation 
5. Time of Accident   Time of reporting for treatment   
Date :   Time :  Date :   Time : 
6. Type of wound  
 Burn   Scald 
7. Wound care   Collagen Type I 
      Heparin 
8. Hospital stay duration 
9. Pain score on visual scale of  1 – 10 Day 2  
 Day 4  
 Average  
 63
10. Time for epithelialisation  7 – 8 days 
       8 – 9 days 
       9 – 10 days  
11. Itching severity on 
 epithelialisation  
Nil Mild Moderate Severe 
12. Compliance for physiotherapy / mobilisation 
Poor Satisfactory Good 
 
13. Sear outcome at 6 months  (Vancouver scar scale) 
A) Pigmentation  
B) Texture 
C) Thickness 
D) Itchiness 
14. Complication of treatment 
 
 
15. Cost of treatment 
 
 0    1    2  
 0   1   2   3   4   5 
 0    1    2     3 
 0    1    2  
   
 
 
 
 
 
Dry type I Collagen HealicollTM and  
Heparin Sodium IP 
 
 
 
 
 
 
How the wound responds immediate post burn 
differentially 
 
 
 
 
 
 
        →    DAY  1 
 
 
 
 
 
 
 
 
DAY 3  → 
 
 
 
 
 
 
 
 
 
        → DAY 5 
 
 
 
 
 
 
 
 
DAY 8  → 
 
Patient as his own control Collagen Vs Heparin 
 
 
 
 
 
 
 
 
Comparative healing in Face 
 
 
 
Collagen     Heparin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collagen     Heparin 
 
 
 
 
Hypopigmentation observed with Healcoll at 6 
months 
 
 
 
 
 
 
Comparative Healing Trunk 
 
 
Heparin    Collagen  
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparative Healing Forearm 
 
 
 
Comparative Healing Forearm 
 
Collagen 
 
 
 
Heparin 
 
 
